Market Overview:

The global non-invasive prenatal testing market reached a value of US$ 2.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2027, exhibiting a CAGR of 17.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, test type, technology, method, application and end-user.

Breakup by Product Type:

• Consumables
• Instruments
   

Breakup by Test Type:

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others
   

Breakup by Technology:

• NGS
• WGS
• Others
   

Breakup by Method:

• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others
   

Breakup by Application:

• Trisomy
• Microdeletion Syndrome
• Others
   

Breakup by End-User:

• Hospitals
• Diagnostic Laboratories
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the top non invasive prenatal testing companies key players being Agilent Technologies, Inc., Berry Genetics, Inc., BGI Genomics Co., Ltd., Eurofins Scientific Services Limited, F. Hoffmann-La Roche Ltd, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., and Yourgene Health plc.

Report Coverage: